Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 142 for “"BRCA1/2"”.
-
Mutationsanalyse im NBS1-Gen bei Patientinnen mit BRCA1/2 negativem familiären und BRCA1/2 negativem sporadischen Mammakarzinom
… in den hochpenetranten Tumorsuppressorgenen BRCA1 oder BRCA2 nachgewiesen werden. Derzeit wird nach weiteren, niedrigpenetranten Suszeptibilitäsgenen geforscht, die einen genetischen Hintergrund für das Mammakarzinom darstellen. Hierbei stehen insbesondere Gene der DNA-Reparatur und …
-
Schwangerschaftsrate und Schwangerschaftsoutcome bei BRCA1/2-Mutationsträgerinnen
… den Einfluss pathogener Varianten (pV) in gBRCA1/2 auf Fertilität, Nutzung reproduktionsmedizinischer Leistungen und Schwangerschaftskomplikationen bei Frauen. Insgesamt wurden 229 Ratsuchende des Zentrums Familiärer Brust- und Eierstockkrebs der Charité (2016–2020) analysiert, darunter 166 …
-
Immunhistochemische und molekulare Untersuchungen BRCA1/2 mutierter Ovarialkarzinome
Hintergrund/Einleitung: Die vorliegende Dissertation befasst sich mit der Frage, ob es immunhistochemisch möglich ist mit verschiedenen diagnostisch relevanten Markern BRCA Mutationen in OVCAs zu detektieren. Das Ovarialkarzinom ist das dritthäufigste Genitalmalignom der Frau. Es ist bis heut ein …
-
Salpingectomy with delayed oophorectomy in BRCA1/2 mutation carriers
Contains fulltext : 173261.pdf (Publisher’s version ) (Open Access)
-
The Experience of Genetic Testing among Latinas with BRCA1/2 mutation
Healthy women with BRCA1 (BReast CAncer gene 1) or BRCA2 (BReast CAncer gene 2), (henceforth, BRCA1/2 mutation) without a diagnosis of breast or ovarian cancer (unaffected), have up to 80% increased lifetime risk of developing breast cancer, and up to 40% increased lifetime risk of ovarian cancer. …
-
Risk Reduction Decision Making in Women with BRCA1/2 Gene Mutations
… testing for gene mutations, a new population of BRCA1/2 women is becoming aware of their increased risk for developing breast and/or ovarian cancer. A salient issue these women face is which risk-reducing option to choose. Little is known about the decision making factors underlying the choice of …
-
Analyse der Lebensqualität mit und ohne prophylaktischer Ovarektomie bei BRCA1/2-Mutationsträgerinnen
Einleitung Die Risikoreduzierende Salpingo-Ovarektomie (RRSO) wird Frauen mit pathogener BRCA-Variante empfohlen, um ihr Lebenszeitrisiko, an einem Ovarialkarzinom zu erkranken, zu reduzieren. In einer Stichprobe von Trägerinnen pathogener BRCA-Varianten wurden Frauen nach RRSO hinsichtlich Angst, …
-
Multidimensional perspective on ovarian cancer risk reduction in BRCA1/2 mutation carriers
Contains fulltext : 183429.pdf (Publisher’s version ) (Open Access)
-
Adaptation to Living with a BRCA1/2 Mutation in Carriers and their Partners
Background: Women who carry BRCA1/2 mutations have a significantly elevated risk for breast and ovarian cancer. While the genetic testing experience can be a major stressor in the lives of these women, it is only one of many to come. Following a positive result, many decisions must be made, …
-
The Role of RNF168 and Novel Genetic Vulnerabilities in BRCA1/2-mutant Cancers
Germline mutations in BRCA1 and BRCA2 (BRCA1/2) genes considerably increase breast and ovarian cancer risk. Given that tumors with these mutations have elevated genomic instability, they exhibit relative vulnerability to certain chemotherapies and targeted treatments based on poly (ADP-ribose) …
-
Structural variants of BRCA1/2 as a novel biomarker of homologous recombination deficiency
… use is largely restricted to patients with a BRCA1/2 mutation. Though BRCA1/2 mutations are the archetypal event resulting in HRD, there is increasing evidence that there are patients with an HRD phenotype beyond those with a BRCA1/2 mutation. This therefore represents an opportunity to …
-
Analysis Of Matched Primary And Recurrent Brca1/2 Mutation-Associated Tumors Identifies Recurrence-Specific Drivers
Patients with inherited germline mutations in BRCA1/2 carry a drastically increased risk of early-onset breast and ovarian cancers. BRCA1/2 mutation-associated tumors respond to therapies that exploit their inherent homologous recombination deficiency, including platinum-based chemotherapy and …
-
How G4 ligands enhance the innate immune response in BRCA1/2- deficient cells and tumours
… et al., 2012). However, tumours lacking BRCA1 and BRCA2 expression, and consequently abrogation of homologous recombination, will accumulate this damage and will therefore be killed more efficiently. Nonetheless, how the pyridostatin induced damage can selectively cause apoptosis in …
-
Body Mass Index and Breast Cancer Risk Among Pre- and Postmenopausal BRCA1/2 Mutation Carriers
Background: BRCA1/2 mutation carriers are at increased risk for breast cancer. It is of interest whether this risk is further impacted by body size, a well-established mediator in breast cancer pathology among the general population. While obesity is a positive predictor of postmenopausal breast …
-
The repair mechanisms of DNA damage induced by G-quadruplexes stabilisation in BRCA1/2-deficient cells
… cancer type 1 or 2 susceptibility protein (BRCA1 or BRCA2 respectively) predispose to the onset of breast and ovarian cancer. Indeed, cells lacking homologous recombination (HR) rely mainly on error-prone mechanisms to repair DNA double-strand breaks (DSBs) and have an inherently increased …
-
Treatment of BRCA1/2-associated breast cancer and identification of mutation carriers among breast cancer patients
… of how breast cancer patients with germline BRCA1/2 mutations should be treated medically and surgically, and furthermore, to characterize the limitations and strengths of different procedures for BRCA testing. In Paper I, the long-term prognosis was assessed in a cohort of early-onset breast …
-
Breast Cancer Risk For Female Relatives of Male Breast Cancer Patients With Negative Brca1/2 Testing
… breast cancer in the context of uninformative BRCA1 and BRCA2 testing. This information may aid in the process of risk assessments for patients and their families following uninformative germline genetic testing. A retrospective chart review was performed to compare the family histories of …
-
“It's Not Only About Them:“ Female Family Members' Understanding of Indeterminate Negative BRCA1/2 Test Results
… negative results are the most common outcome of BRCA1/2 mutation testing. Little is known about family members' understanding of indeterminate negative BRCA1/2 test results. The purpose of this qualitative descriptive study was to investigate how daughters and sisters received and understood …
-
Ιστολογικά και επιδημιολογικά χαρακτηριστικά γυναικών με καρκίνο μαστού / ωοθηκών που φέρουν μεταλλάξεις στα γονίδια BRCA1/2.
… και των σημαντικότερων σχετικών γονιδίων (BRCA1, BRCA2), είναι δυνατόν να ευθύνονται μέχρι και για το 10% των περιπτώσεων καρκίνου του μαστού στις αναπτυγμένες χώρες. Ο καρκίνος των ωοθηκών αποτελεί τη 2η αιτία θανάτου από γυναικολογικό καρκίνο μετά τον καρκίνο του μαστού και την 4η αιτία …
Page 1 of 8